A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes
Purpose Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine, l...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2014-10, Vol.22 (10), p.2677-2685 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2685 |
|---|---|
| container_issue | 10 |
| container_start_page | 2677 |
| container_title | Supportive care in cancer |
| container_volume | 22 |
| creator | Weaver, Andrew Love, Sharon B. Larsen, Mark Shanyinde, Milensu Waters, Rachel Grainger, Lisa Shearwood, Vanessa Brooks, Claire Gibson, Oliver Young, Annie M. Tarassenko, Lionel |
| description | Purpose
Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine, level of toxicity and perceived supportive care.
Methods
Patients with breast or colorectal cancer receiving capecitabine completed a symptom, temperature and dose diary twice a day using a mobile phone application. This information was encrypted and automatically transmitted in real time to a secure server, with moderate levels of toxicity automatically prompting self-care symptom management messages on the screen of the patient’s mobile phone or in severe cases, a call from a specialist nurse to advise on care according to an agreed protocol.
Results
Patients (
n
= 26) completed the mobile phone diary on 92.6 % of occasions. Twelve patients had a maximum toxicity grade of 3 (46.2 %). The average dose intensity for all patients as a percentage of standard dose was 90 %. In eight patients, the dose of capecitabine was reduced, and in eight patients, the dose of capecitabine was increased. Patients and healthcare professionals involved felt reassured by the novel monitoring system, in particular, during out of hours.
Conclusion
It is possible to optimise the individual dose of oral chemotherapy safely including dose increase and to manage chemotherapy side effects effectively using real-time mobile phone monitoring of toxicity parameters entered by the patient. |
| doi_str_mv | 10.1007/s00520-014-2224-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1559511670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A384207788</galeid><sourcerecordid>A384207788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-e080ab3c7ba79081a36cd4224cbfc676b03b20ec08e1d8b82c4415c4639676283</originalsourceid><addsrcrecordid>eNp1UU1rFTEUDWKxz-oPcCMB11NvviYz7h5Fq1BwU9chyWT6Ut5MYpIBH7jwR_gL_SXN8OoXtGQRcu855-aeg9ArAucEQL7NAIJCA4Q3lFLekCdoQzhjjWSsf4o20HPScCbEKXqe8y0AkVLQZ-iUcikJ7fsN-r7F0e9Dwbksw-EdHkJ2WA86Fl18mHEYsdXRWV-08bPDS_bzDZ6C8XuH4y7UUgnffO0fanX2JaQV8OvHT5yXGEMq6zNWMTeXjP2My875hHdhcvkFOhn1PruX9_cZ-vLh_fXFx-bq8-Wni-1VYwX0pXHQgTbMSqNlDx3RrLUDrwtbM9pWtgaYoeAsdI4Mnemo5ZwIy1vW1y7t2Bl6c9SNKXxdXC7qNixpriMVEaIXhLQS_qJu9N4pP4-hJG0nn63aso5TkLJbtc4fQNUzuMnb6sdYnfmfQI4Em0LOyY0qJj_pdFAE1BqjOsaoaoxqjVGRynl9_-HFTG74w_idWwXQIyDH1W-X_tnoUdU71X6ocg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559511670</pqid></control><display><type>article</type><title>A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Weaver, Andrew ; Love, Sharon B. ; Larsen, Mark ; Shanyinde, Milensu ; Waters, Rachel ; Grainger, Lisa ; Shearwood, Vanessa ; Brooks, Claire ; Gibson, Oliver ; Young, Annie M. ; Tarassenko, Lionel</creator><creatorcontrib>Weaver, Andrew ; Love, Sharon B. ; Larsen, Mark ; Shanyinde, Milensu ; Waters, Rachel ; Grainger, Lisa ; Shearwood, Vanessa ; Brooks, Claire ; Gibson, Oliver ; Young, Annie M. ; Tarassenko, Lionel</creatorcontrib><description>Purpose
Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine, level of toxicity and perceived supportive care.
Methods
Patients with breast or colorectal cancer receiving capecitabine completed a symptom, temperature and dose diary twice a day using a mobile phone application. This information was encrypted and automatically transmitted in real time to a secure server, with moderate levels of toxicity automatically prompting self-care symptom management messages on the screen of the patient’s mobile phone or in severe cases, a call from a specialist nurse to advise on care according to an agreed protocol.
Results
Patients (
n
= 26) completed the mobile phone diary on 92.6 % of occasions. Twelve patients had a maximum toxicity grade of 3 (46.2 %). The average dose intensity for all patients as a percentage of standard dose was 90 %. In eight patients, the dose of capecitabine was reduced, and in eight patients, the dose of capecitabine was increased. Patients and healthcare professionals involved felt reassured by the novel monitoring system, in particular, during out of hours.
Conclusion
It is possible to optimise the individual dose of oral chemotherapy safely including dose increase and to manage chemotherapy side effects effectively using real-time mobile phone monitoring of toxicity parameters entered by the patient.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-014-2224-1</identifier><identifier>PMID: 24771299</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Adult ; Aged ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - toxicity ; Antimitotic agents ; Antineoplastic agents ; Breast Neoplasms - drug therapy ; Cancer ; Cancer patients ; Capecitabine ; Cell Phone ; Cellular telephones ; Chemotherapy ; Colorectal cancer ; Colorectal Neoplasms - drug therapy ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - toxicity ; Drug dosages ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Fluorouracil - toxicity ; Humans ; Male ; Medical personnel ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Middle Aged ; Monitoring, Physiologic - instrumentation ; Monitoring, Physiologic - methods ; Nursing ; Nursing Research ; Oncology ; Original Article ; Pain Medicine ; Pilot Projects ; Rehabilitation Medicine ; Side effects ; Telemedicine ; Toxicity]]></subject><ispartof>Supportive care in cancer, 2014-10, Vol.22 (10), p.2677-2685</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>COPYRIGHT 2014 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-e080ab3c7ba79081a36cd4224cbfc676b03b20ec08e1d8b82c4415c4639676283</citedby><cites>FETCH-LOGICAL-c509t-e080ab3c7ba79081a36cd4224cbfc676b03b20ec08e1d8b82c4415c4639676283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-014-2224-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-014-2224-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24771299$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weaver, Andrew</creatorcontrib><creatorcontrib>Love, Sharon B.</creatorcontrib><creatorcontrib>Larsen, Mark</creatorcontrib><creatorcontrib>Shanyinde, Milensu</creatorcontrib><creatorcontrib>Waters, Rachel</creatorcontrib><creatorcontrib>Grainger, Lisa</creatorcontrib><creatorcontrib>Shearwood, Vanessa</creatorcontrib><creatorcontrib>Brooks, Claire</creatorcontrib><creatorcontrib>Gibson, Oliver</creatorcontrib><creatorcontrib>Young, Annie M.</creatorcontrib><creatorcontrib>Tarassenko, Lionel</creatorcontrib><title>A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine, level of toxicity and perceived supportive care.
Methods
Patients with breast or colorectal cancer receiving capecitabine completed a symptom, temperature and dose diary twice a day using a mobile phone application. This information was encrypted and automatically transmitted in real time to a secure server, with moderate levels of toxicity automatically prompting self-care symptom management messages on the screen of the patient’s mobile phone or in severe cases, a call from a specialist nurse to advise on care according to an agreed protocol.
Results
Patients (
n
= 26) completed the mobile phone diary on 92.6 % of occasions. Twelve patients had a maximum toxicity grade of 3 (46.2 %). The average dose intensity for all patients as a percentage of standard dose was 90 %. In eight patients, the dose of capecitabine was reduced, and in eight patients, the dose of capecitabine was increased. Patients and healthcare professionals involved felt reassured by the novel monitoring system, in particular, during out of hours.
Conclusion
It is possible to optimise the individual dose of oral chemotherapy safely including dose increase and to manage chemotherapy side effects effectively using real-time mobile phone monitoring of toxicity parameters entered by the patient.</description><subject>Adult</subject><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - toxicity</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Capecitabine</subject><subject>Cell Phone</subject><subject>Cellular telephones</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - toxicity</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Fluorouracil - toxicity</subject><subject>Humans</subject><subject>Male</subject><subject>Medical personnel</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Monitoring, Physiologic - instrumentation</subject><subject>Monitoring, Physiologic - methods</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Pilot Projects</subject><subject>Rehabilitation Medicine</subject><subject>Side effects</subject><subject>Telemedicine</subject><subject>Toxicity</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1UU1rFTEUDWKxz-oPcCMB11NvviYz7h5Fq1BwU9chyWT6Ut5MYpIBH7jwR_gL_SXN8OoXtGQRcu855-aeg9ArAucEQL7NAIJCA4Q3lFLekCdoQzhjjWSsf4o20HPScCbEKXqe8y0AkVLQZ-iUcikJ7fsN-r7F0e9Dwbksw-EdHkJ2WA86Fl18mHEYsdXRWV-08bPDS_bzDZ6C8XuH4y7UUgnffO0fanX2JaQV8OvHT5yXGEMq6zNWMTeXjP2My875hHdhcvkFOhn1PruX9_cZ-vLh_fXFx-bq8-Wni-1VYwX0pXHQgTbMSqNlDx3RrLUDrwtbM9pWtgaYoeAsdI4Mnemo5ZwIy1vW1y7t2Bl6c9SNKXxdXC7qNixpriMVEaIXhLQS_qJu9N4pP4-hJG0nn63aso5TkLJbtc4fQNUzuMnb6sdYnfmfQI4Em0LOyY0qJj_pdFAE1BqjOsaoaoxqjVGRynl9_-HFTG74w_idWwXQIyDH1W-X_tnoUdU71X6ocg</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Weaver, Andrew</creator><creator>Love, Sharon B.</creator><creator>Larsen, Mark</creator><creator>Shanyinde, Milensu</creator><creator>Waters, Rachel</creator><creator>Grainger, Lisa</creator><creator>Shearwood, Vanessa</creator><creator>Brooks, Claire</creator><creator>Gibson, Oliver</creator><creator>Young, Annie M.</creator><creator>Tarassenko, Lionel</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20141001</creationdate><title>A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes</title><author>Weaver, Andrew ; Love, Sharon B. ; Larsen, Mark ; Shanyinde, Milensu ; Waters, Rachel ; Grainger, Lisa ; Shearwood, Vanessa ; Brooks, Claire ; Gibson, Oliver ; Young, Annie M. ; Tarassenko, Lionel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-e080ab3c7ba79081a36cd4224cbfc676b03b20ec08e1d8b82c4415c4639676283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - toxicity</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Capecitabine</topic><topic>Cell Phone</topic><topic>Cellular telephones</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - toxicity</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Fluorouracil - toxicity</topic><topic>Humans</topic><topic>Male</topic><topic>Medical personnel</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Monitoring, Physiologic - instrumentation</topic><topic>Monitoring, Physiologic - methods</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Pilot Projects</topic><topic>Rehabilitation Medicine</topic><topic>Side effects</topic><topic>Telemedicine</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weaver, Andrew</creatorcontrib><creatorcontrib>Love, Sharon B.</creatorcontrib><creatorcontrib>Larsen, Mark</creatorcontrib><creatorcontrib>Shanyinde, Milensu</creatorcontrib><creatorcontrib>Waters, Rachel</creatorcontrib><creatorcontrib>Grainger, Lisa</creatorcontrib><creatorcontrib>Shearwood, Vanessa</creatorcontrib><creatorcontrib>Brooks, Claire</creatorcontrib><creatorcontrib>Gibson, Oliver</creatorcontrib><creatorcontrib>Young, Annie M.</creatorcontrib><creatorcontrib>Tarassenko, Lionel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weaver, Andrew</au><au>Love, Sharon B.</au><au>Larsen, Mark</au><au>Shanyinde, Milensu</au><au>Waters, Rachel</au><au>Grainger, Lisa</au><au>Shearwood, Vanessa</au><au>Brooks, Claire</au><au>Gibson, Oliver</au><au>Young, Annie M.</au><au>Tarassenko, Lionel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>22</volume><issue>10</issue><spage>2677</spage><epage>2685</epage><pages>2677-2685</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine, level of toxicity and perceived supportive care.
Methods
Patients with breast or colorectal cancer receiving capecitabine completed a symptom, temperature and dose diary twice a day using a mobile phone application. This information was encrypted and automatically transmitted in real time to a secure server, with moderate levels of toxicity automatically prompting self-care symptom management messages on the screen of the patient’s mobile phone or in severe cases, a call from a specialist nurse to advise on care according to an agreed protocol.
Results
Patients (
n
= 26) completed the mobile phone diary on 92.6 % of occasions. Twelve patients had a maximum toxicity grade of 3 (46.2 %). The average dose intensity for all patients as a percentage of standard dose was 90 %. In eight patients, the dose of capecitabine was reduced, and in eight patients, the dose of capecitabine was increased. Patients and healthcare professionals involved felt reassured by the novel monitoring system, in particular, during out of hours.
Conclusion
It is possible to optimise the individual dose of oral chemotherapy safely including dose increase and to manage chemotherapy side effects effectively using real-time mobile phone monitoring of toxicity parameters entered by the patient.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24771299</pmid><doi>10.1007/s00520-014-2224-1</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2014-10, Vol.22 (10), p.2677-2685 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_journals_1559511670 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - toxicity Antimitotic agents Antineoplastic agents Breast Neoplasms - drug therapy Cancer Cancer patients Capecitabine Cell Phone Cellular telephones Chemotherapy Colorectal cancer Colorectal Neoplasms - drug therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - toxicity Drug dosages Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Fluorouracil - toxicity Humans Male Medical personnel Medical research Medicine Medicine & Public Health Medicine, Experimental Middle Aged Monitoring, Physiologic - instrumentation Monitoring, Physiologic - methods Nursing Nursing Research Oncology Original Article Pain Medicine Pilot Projects Rehabilitation Medicine Side effects Telemedicine Toxicity |
| title | A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T20%3A56%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pilot%20study:%20dose%20adaptation%20of%20capecitabine%20using%20mobile%20phone%20toxicity%20monitoring%20%E2%80%94%20supporting%20patients%20in%20their%20homes&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Weaver,%20Andrew&rft.date=2014-10-01&rft.volume=22&rft.issue=10&rft.spage=2677&rft.epage=2685&rft.pages=2677-2685&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-014-2224-1&rft_dat=%3Cgale_proqu%3EA384207788%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559511670&rft_id=info:pmid/24771299&rft_galeid=A384207788&rfr_iscdi=true |